Table 4.
Univariate analysis of impact of various characteristics on patient survival
| Characteristics | n |
DFS |
P value |
OS |
P value | ||||
| Mean (mo)1 | 3-yr2 | 5- yr2 | Mean (mo)1 | 3- yr2 | 5- yr2 | ||||
| Sex | |||||||||
| Male | 90 | 61.8 ± 25.9 | 81.1% | 74.4% | 0.803 | 65.5 ± 22.2 | 84.4% | 79.9% | 0.855 |
| Female | 35 | 65.6 ± 24.6 | 82.9% | 76.9% | 69.5 ± 20.1 | 88.6% | 79.8% | ||
| Age (yr) | |||||||||
| < 60 | 73 | 63.3 ± 26.3 | 80.1% | 71.1% | 0.533 | 68.4 ± 22.0 | 86.3% | 80.7% | 0.908 |
| ≥ 60 | 52 | 62.4 ± 24.6 | 82.7% | 80.7% | 64.2 ± 21.5 | 84.6% | 78.7% | ||
| Tumor size (cm) | |||||||||
| ≤ 3 | 48 | 62.5 ± 26.1 | 81.2% | 77.0% | 0.571 | 65.0 ± 22.4 | 83.3% | 79.2% | 0.962 |
| > 3 | 77 | 63.2 ± 25.3 | 81.8% | 74.0% | 67.7 ± 21.6 | 87.0% | 80.3% | ||
| BMI | |||||||||
| < 25 | 100 | 60.5 ± 26.8 | 77.0% | 69.9% | 0.024 | 65.3 ± 22.7 | 82.0% | 76.9% | 0.050 |
| ≥ 25 | 25 | 72.7 ± 16.6 | 96.0% | 96.0% | 72.1 ± 17.0 | 96.0% | 92.0% | ||
| Tumor grade | |||||||||
| 1 | 28 | 64.7 ± 28.0 | 78.6% | 75.0% | 0.852 | 69.4 ± 22.5 | 85.7% | 78.6% | 0.931 |
| 2, 3 | 97 | 62.4 ± 25.0 | 82.5% | 75.2% | 65.6 ± 21.7 | 85.6% | 80.2% | ||
| cTNM | |||||||||
| II | 39 | 69.2 ± 23.2 | 87.2% | 84.6% | 0.067 | 71.9 ± 18.8 | 92.3% | 87.2% | 0.137 |
| III | 86 | 60.0 ± 26.2 | 79.1% | 70.7% | 64.2 ± 22.8 | 82.6% | 76.4% | ||
| CEA (ng/mL) | |||||||||
| < 5 | 62 | 77.0 ± 4.1 | 69.2% | 69.2% | 0.789 | 79.6 ± 3.7 | 80.6% | 73.9% | 0.384 |
| ≥ 5 | 58 | 80.4 ± 4.3 | 82.8% | 74.0% | 86.1 ± 3.4 | 89.7% | 84.5% | ||
| CA19-9 (U/mL) | |||||||||
| < 35 | 102 | 81.3 ± 3.1 | 83.3% | 75.4% | 0.174 | 84.2 ± 2.7 | 86.3% | 80.2% | 0.597 |
| ≥ 35 | 18 | 68.1 ± 9.2 | 72.2% | 66.7% | 78.3 ± 7.8 | 77.8% | 72.2% | ||
| CRT efficacy | |||||||||
| Poor | 74 | 60.7 ± 27.2 | 78.4% | 67.5% | 0.031 | 66.2 ± 23.2 | 83.8% | 75.6% | 0.144 |
| Good | 51 | 66.1 ± 23.0 | 90.2% | 86.0% | 67.3 ± 19.9 | 88.2% | 86.1% | ||
| ypTNM | |||||||||
| ypcr,I, II | 91 | 66.1 ± 24.0 | 85.7% | 82.3% | 0.005 | 68.5 ± 20.1 | 89.0% | 84.4% | 0.041 |
| III | 34 | 54.3 ± 28.0 | 70.6% | 55.6% | 61.6 ± 25.5 | 76.5% | 67.6% | ||
| Adjuvant CT | |||||||||
| No | 21 | 60.2 ± 31.5 | 71.4% | 71.4% | 0.385 | 63.5 ± 26.5 | 76.2% | 66.3% | 0.229 |
| Yes | 104 | 63.5 ± 24.3 | 83.7% | 75.8% | 67.3 ± 20.8 | 87.5% | 82.7% | ||
| OME | |||||||||
| Non- EOU | 62 | 70.0 ± 25.8 | 85.5% | 75.6% | 0.658 | 73.9 ± 21.9 | 90.3% | 82.0% | 0.754 |
| EOU | 63 | 55.9 ± 23.5 | 77.8% | 74.6% | 59.5 ± 19.5 | 82.5% | 77.6% | ||
| OME (200 mg) | |||||||||
| Non-EOG | 96 | 62.0 ± 28.2 | 77.1% | 69.6% | 0.032 | 66.9 ± 24.1 | 82.3% | 76.9% | 0.092 |
| EOG | 29 | 65.9 ± 13.3 | 96.6% | 46.7% | 65.8 ± 12.0 | 96.6% | 89.5% | ||
1
Mean ± SD (mo);
2
Three or 5 years survival rate. EOU: Eligible OME users; Non-EOU: Non-eligible OME users; EOG: Effective OME group; Non-EOG: Non-effective OME group; BMI: Body mass index; adjuvant CT: Adjuvant chemotherapy.